Psilocybin's Neuroplasticity Mechanism: 5-HT2A, Glutamate, BDNF and mTOR

Psilocybin is a **pro-drug**: it is dephosphorylated in the body to **psilocin**, which is the active compound. Psilocin acts as an agonist at serotonin receptors, principally **5-HT2A**, with additional activity at 5-HT2C and 5-HT1A. 5-HT2A agonism explains the subjective effects — the receptor is densely expressed in the neocortex, particularly on layer V pyramidal neurons — and 5-HT2A antagonists block the psychedelic experience, which is the strongest evidence that this receptor is the relevant target. ## The plasticity cascade The therapeutic hypothesis rests on a downstream signalling chain rather than on acute serotonergic activity: 1. **5-HT2A activation** on cortical pyramidal neurons increases extracellular **glutamate**. 2. Glutamate activates **AMPA receptors**, central to synaptic strengthening and learning. 3. This drives release of **BDNF** (brain-derived neurotrophic factor), which supports neuronal survival and growth. 4. BDNF signalling activates **mTOR**, driving the protein synthesis required to build new synaptic structure. The observable end of this chain in preclinical work is structural: a single dose produces rapid and relatively sustained growth of **dendritic spines** in frontal cortex, with increased synaptic density. A pig-brain study found a single dose increased synaptic density while *decreasing* 5-HT2A receptor density — consistent with receptor downregulation following strong agonism. This is why psilocybin is grouped with ketamine as a **psychoplastogen**: a compound producing rapid, lasting increases in structural plasticity after brief exposure. It also motivates the hypothesis that the therapeutic window is a period of heightened plasticity *after* the acute experience, during which existing patterns are more revisable — the rationale for the psychotherapy wrapper around dosing sessions. ## The regional caveat The plasticity effects are strongest where 5-HT2A is dense, which is neocortex. The **hippocampus** — the region where one would most want neurogenesis and synaptic repair for dementia — is comparatively richer in **5-HT1A** than 5-HT2A, so the pro-plasticity effect there should be weaker. This is an early and specific reason for caution about the neurodegeneration hypothesis: the mechanism is not uniformly distributed across the brain, and it is thinnest exactly where the pathology of interest concentrates. See Psychedelics for Neurodegeneration: Huntington's, Dementia, and the Evidence Gap.